<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000845</url>
  </required_header>
  <id_info>
    <org_study_id>AVEG 021</org_study_id>
    <nct_id>NCT00000845</nct_id>
  </id_info>
  <brief_title>A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects</brief_title>
  <official_title>A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate an HIV synthetic lipopeptide candidate vaccine component, P3C541b, at two dose&#xD;
      levels, administered subcutaneously (s.c.) in a randomized, double-blind, placebo controlled&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prospective volunteers will be screened and HLA typed for Class I MHC haplotypes. Only&#xD;
      volunteers possessing HLA alleles A33, B8, B27, B35 or Bw62 or any combination thereof will&#xD;
      be enrolled in the study. Subjects will be allocated to 1 of 2 study groups. Group 1 will&#xD;
      receive 70 mcg of P3C541b or the placebo and Group II will receive 350 mcg of P3C541b or the&#xD;
      placebo. NOTE: Enrollment for Group II wil not begin until at least 5 Group I participants&#xD;
      have reached day 14 without serious adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>P3C541b Lipopeptide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have or be:&#xD;
&#xD;
          -  Healthy&#xD;
&#xD;
          -  Negative ELISA for HIV.&#xD;
&#xD;
          -  One or more HLA alleles:&#xD;
&#xD;
          -  A33, B8, B27, B35, or Bw62.&#xD;
&#xD;
          -  Negative for Hepatitis B surface antigen.&#xD;
&#xD;
          -  Normal urine dipstick.&#xD;
&#xD;
          -  Normal history and physical examination.&#xD;
&#xD;
          -  Availability for follow-up planned duration of the study (12 months).&#xD;
&#xD;
          -  Viable EBV line prior to enrollment.&#xD;
&#xD;
        Risk behavior: Required:&#xD;
&#xD;
          -  Lower risk sexual behavior as defined by AVEG.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with any of the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Medical or psychiatric condition or occupational responsibilities, which preclude&#xD;
             subject compliance with the protocol (e.g., recent suicidal ideation or present&#xD;
             psychosis).&#xD;
&#xD;
          -  Active syphilis. NOTE: If the serology is documented to be false positive due to a&#xD;
             remote (&gt; 6 months) treated infection, the volunteer is eligible.&#xD;
&#xD;
          -  Hepatitis B surface antigenemia.&#xD;
&#xD;
          -  Active tuberculosis. NOTE: Volunteers with a positive PPD and a normal chest X-Ray&#xD;
             showing no evidence of TB and not requiring INH therapy are eligible.&#xD;
&#xD;
        Patients with any of the following prior conditions are excluded:&#xD;
&#xD;
          -  History of immunodeficiency, chronic illness, malignancy, autoimmune disease.&#xD;
&#xD;
          -  History of cancer, unless there has been surgical excision followed by a sufficient&#xD;
             observation period to give a reasonable assurance of a cure.&#xD;
&#xD;
          -  History of anaphylaxis or history of other serious adverse reactions to vaccines.&#xD;
&#xD;
          -  History of serious allergic reaction to any substance, requiring hospitalization or&#xD;
             emergent medical care.&#xD;
&#xD;
          -  History of suicide attempts or past psychosis.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  History of use of immunosuppressive medication.&#xD;
&#xD;
          -  Live attenuated vaccines within 60 days of study.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Medically indicated subunit or killed vaccines (e.g., influenza, pneumococcal) are not&#xD;
             exclusionary but should be given at least 2 weeks away from HIV immunizations.&#xD;
&#xD;
          -  Use of experimental agents within 30 days prior to study.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Receipt of blood products or immunoglobulin in the past 6 months.&#xD;
&#xD;
        Risk Behavior:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Subjects with identifiable higher risk behavior for HIV infection as determined by&#xD;
             screening questionnaire designed to identify risk factors for HIV infection.&#xD;
&#xD;
          -  History of injection drug use within the last 12 months prior to enrollment.&#xD;
&#xD;
          -  Higher or intermediate risk sexual behavior as defined by AVEG.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Schwartz D</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Univ / School of Hygiene &amp; Public Health</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>212051901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Univ Hosp</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Washington / Pacific Med Ctr</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2002</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Vaccines, Synthetic</keyword>
  <keyword>AIDS Vaccines</keyword>
  <keyword>HIV Seronegativity</keyword>
  <keyword>HIV Preventive Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

